The preventable burden of pneumococcal disease in the developing world

Clicks: 470
ID: 111098
2007
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #10 of 86 articles by views in Vaccine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The efficacy of pneumococcal conjugate vaccines (PCV) and their remarkable success in operational use in North America challenge us to define the burden of pneumococcal disease and the likely benefits of PCV use in developing countries. Community-based incidence studies of invasive pneumococcal dise …
Reference Key
ja2007vaccinethe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Scott JA;;
Journal Vaccine
Year 2007
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/17028081
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't Child Infant newborn preschool vaccines pmid:17028081 doi:10.1016/j.vaccine.2006.09.008 j a g scott developing countries pneumococcal infections / epidemiology* pneumococcal infections / mortality pneumococcal infections / prevention & control* pneumococcal vaccines / immunology pneumococcal vaccines / therapeutic use* conjugate / immunology conjugate / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.